# Nob Hill Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nob-hill-therapeutics

- Industry: Biotechnology
- Headquarters: Albuquerque, US
- Website: www.nobhilltherapeutics.com
- Total disclosed funding: $1.8M
- Latest round: Series A (Jul 26, 2024)
- Investors on record: 3

## About

Nob Hill Therapeutics, Inc., based in Albuquerque, US, specializes in the creation of innovative inhalation therapies aimed at improving treatment for lung diseases, focusing on advanced drug delivery methods for optimal patient outcomes.Founded in 2016, Nob Hill Therapeutics, Inc. is engaged in the development of inhalation medicines for patients with lung-related conditions. The company has not undergone any notable pivots and operates independently without known subsidiaries. The founder's background is not specified. As of July 26, 2024, the company completed its Series A funding round, raising USD 1.751 mn, led by Tramway Venture Partners with participation from Tech Coast Angels and VIC Technology Venture Development. The total amount raised by the company is USD 1.751 mn, with a current valuation of USD 9.984 mn.Nob Hill Therapeutics specializes in developing innovative inhalation medicines that enhance lung delivery for patients suffering from lung diseases. The company is focused on re-envisioning delivery methods for high-dose therapies that address conditions with limited treatment options. Their products include advanced technologies designed to improve the efficiency of drug delivery directly to the lungs, thereby enhancing patient outcomes. The primary end-users are patients with respiratory ailments, as well as healthcare providers and institutions involved in respiratory care. The company has a presence in various geographical markets, including North America and Europe, where the demand for effective lung therapies is significant.Nob Hill Therapeutics generates revenue through partnerships and collaborations within the healthcare sector, emphasizing the development and commercialization of its inhalation technologies. The firm engages in B2B transactions with healthcare entities, research institutions, and pharmaceutical companies seeking to leverage its products in clinical settings. Revenue streams are derived from licensing agreements, joint ventures, and direct sales of proprietary inhalation systems, often structured through negotiated contracts that include milestone payments and royalties based on product performance. Pricing plans are tailored to the needs of healthcare providers, ensuring broad accessibility of Nob Hill's solutions.In August 2024, Nob Hill Therapeutics, Inc. raised USD 1.75 mn in Series A funding, led by Tramway Venture Partners, with participation from other investors including Tech Coast Angels and VIC Technology Venture Development. The funding will be used to support the development of their technology and therapeutics. The company aims to expand its product offerings and explore new markets. Specific future products are not detailed, but the focus remains on enhancing their inhalation technologies and potentially launching new therapies for lung diseases. The targeted markets for expansion include North America and Europe, aligning with their existing presence in these regions.

## Funding rounds

- Series A, Jul 26, 2024, $1.8M — Tech Coast Angels, Tramway Venture Partners, VIC Technology Venture Development

## Investors

- Tech Coast Angels — Series A
- Tramway Venture Partners (https://capitalatlas.ai/funds/tramway-venture-partners) — Series A
- VIC Technology Venture Development — Series A